Recombinant Protein Drugs Market
1 Study Coverage
1.1 Recombinant Protein Drugs Product Introduction
1.2 Market by Type
1.2.1 Global Recombinant Protein Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Recombinant DNA
1.2.3 Recombinant RNA
1.3 Market by Application
1.3.1 Global Recombinant Protein Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Pharmaceutical Industry
1.3.3 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Recombinant Protein Drugs Sales Estimates and Forecasts 2017-2028
2.2 Global Recombinant Protein Drugs Revenue Estimates and Forecasts 2017-2028
2.3 Global Recombinant Protein Drugs Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Recombinant Protein Drugs Sales by Region
2.4.1 Global Recombinant Protein Drugs Sales by Region (2017-2022)
2.4.2 Global Sales Recombinant Protein Drugs by Region (2023-2028)
2.5 Global Recombinant Protein Drugs Revenue by Region
2.5.1 Global Recombinant Protein Drugs Revenue by Region (2017-2022)
2.5.2 Global Recombinant Protein Drugs Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Recombinant Protein Drugs Sales by Manufacturers
3.1.1 Global Top Recombinant Protein Drugs Manufacturers by Sales (2017-2022)
3.1.2 Global Recombinant Protein Drugs Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Recombinant Protein Drugs in 2021
3.2 Global Recombinant Protein Drugs Revenue by Manufacturers
3.2.1 Global Recombinant Protein Drugs Revenue by Manufacturers (2017-2022)
3.2.2 Global Recombinant Protein Drugs Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Recombinant Protein Drugs Revenue in 2021
3.3 Global Recombinant Protein Drugs Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Recombinant Protein Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Recombinant Protein Drugs Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Recombinant Protein Drugs Sales by Type
4.1.1 Global Recombinant Protein Drugs Historical Sales by Type (2017-2022)
4.1.2 Global Recombinant Protein Drugs Forecasted Sales by Type (2023-2028)
4.1.3 Global Recombinant Protein Drugs Sales Market Share by Type (2017-2028)
4.2 Global Recombinant Protein Drugs Revenue by Type
4.2.1 Global Recombinant Protein Drugs Historical Revenue by Type (2017-2022)
4.2.2 Global Recombinant Protein Drugs Forecasted Revenue by Type (2023-2028)
4.2.3 Global Recombinant Protein Drugs Revenue Market Share by Type (2017-2028)
4.3 Global Recombinant Protein Drugs Price by Type
4.3.1 Global Recombinant Protein Drugs Price by Type (2017-2022)
4.3.2 Global Recombinant Protein Drugs Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Recombinant Protein Drugs Sales by Application
5.1.1 Global Recombinant Protein Drugs Historical Sales by Application (2017-2022)
5.1.2 Global Recombinant Protein Drugs Forecasted Sales by Application (2023-2028)
5.1.3 Global Recombinant Protein Drugs Sales Market Share by Application (2017-2028)
5.2 Global Recombinant Protein Drugs Revenue by Application
5.2.1 Global Recombinant Protein Drugs Historical Revenue by Application (2017-2022)
5.2.2 Global Recombinant Protein Drugs Forecasted Revenue by Application (2023-2028)
5.2.3 Global Recombinant Protein Drugs Revenue Market Share by Application (2017-2028)
5.3 Global Recombinant Protein Drugs Price by Application
5.3.1 Global Recombinant Protein Drugs Price by Application (2017-2022)
5.3.2 Global Recombinant Protein Drugs Price Forecast by Application (2023-2028)
6 North America
6.1 North America Recombinant Protein Drugs Market Size by Type
6.1.1 North America Recombinant Protein Drugs Sales by Type (2017-2028)
6.1.2 North America Recombinant Protein Drugs Revenue by Type (2017-2028)
6.2 North America Recombinant Protein Drugs Market Size by Application
6.2.1 North America Recombinant Protein Drugs Sales by Application (2017-2028)
6.2.2 North America Recombinant Protein Drugs Revenue by Application (2017-2028)
6.3 North America Recombinant Protein Drugs Market Size by Country
6.3.1 North America Recombinant Protein Drugs Sales by Country (2017-2028)
6.3.2 North America Recombinant Protein Drugs Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Recombinant Protein Drugs Market Size by Type
7.1.1 Europe Recombinant Protein Drugs Sales by Type (2017-2028)
7.1.2 Europe Recombinant Protein Drugs Revenue by Type (2017-2028)
7.2 Europe Recombinant Protein Drugs Market Size by Application
7.2.1 Europe Recombinant Protein Drugs Sales by Application (2017-2028)
7.2.2 Europe Recombinant Protein Drugs Revenue by Application (2017-2028)
7.3 Europe Recombinant Protein Drugs Market Size by Country
7.3.1 Europe Recombinant Protein Drugs Sales by Country (2017-2028)
7.3.2 Europe Recombinant Protein Drugs Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Recombinant Protein Drugs Market Size by Type
8.1.1 Asia Pacific Recombinant Protein Drugs Sales by Type (2017-2028)
8.1.2 Asia Pacific Recombinant Protein Drugs Revenue by Type (2017-2028)
8.2 Asia Pacific Recombinant Protein Drugs Market Size by Application
8.2.1 Asia Pacific Recombinant Protein Drugs Sales by Application (2017-2028)
8.2.2 Asia Pacific Recombinant Protein Drugs Revenue by Application (2017-2028)
8.3 Asia Pacific Recombinant Protein Drugs Market Size by Region
8.3.1 Asia Pacific Recombinant Protein Drugs Sales by Region (2017-2028)
8.3.2 Asia Pacific Recombinant Protein Drugs Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Recombinant Protein Drugs Market Size by Type
9.1.1 Latin America Recombinant Protein Drugs Sales by Type (2017-2028)
9.1.2 Latin America Recombinant Protein Drugs Revenue by Type (2017-2028)
9.2 Latin America Recombinant Protein Drugs Market Size by Application
9.2.1 Latin America Recombinant Protein Drugs Sales by Application (2017-2028)
9.2.2 Latin America Recombinant Protein Drugs Revenue by Application (2017-2028)
9.3 Latin America Recombinant Protein Drugs Market Size by Country
9.3.1 Latin America Recombinant Protein Drugs Sales by Country (2017-2028)
9.3.2 Latin America Recombinant Protein Drugs Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Recombinant Protein Drugs Market Size by Type
10.1.1 Middle East and Africa Recombinant Protein Drugs Sales by Type (2017-2028)
10.1.2 Middle East and Africa Recombinant Protein Drugs Revenue by Type (2017-2028)
10.2 Middle East and Africa Recombinant Protein Drugs Market Size by Application
10.2.1 Middle East and Africa Recombinant Protein Drugs Sales by Application (2017-2028)
10.2.2 Middle East and Africa Recombinant Protein Drugs Revenue by Application (2017-2028)
10.3 Middle East and Africa Recombinant Protein Drugs Market Size by Country
10.3.1 Middle East and Africa Recombinant Protein Drugs Sales by Country (2017-2028)
10.3.2 Middle East and Africa Recombinant Protein Drugs Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Novo Nordisk
11.1.1 Novo Nordisk Corporation Information
11.1.2 Novo Nordisk Overview
11.1.3 Novo Nordisk Recombinant Protein Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Novo Nordisk Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Novo Nordisk Recent Developments
11.2 Amgen
11.2.1 Amgen Corporation Information
11.2.2 Amgen Overview
11.2.3 Amgen Recombinant Protein Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Amgen Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Amgen Recent Developments
11.3 Sanofi
11.3.1 Sanofi Corporation Information
11.3.2 Sanofi Overview
11.3.3 Sanofi Recombinant Protein Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Sanofi Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Sanofi Recent Developments
11.4 Eli Lilly
11.4.1 Eli Lilly Corporation Information
11.4.2 Eli Lilly Overview
11.4.3 Eli Lilly Recombinant Protein Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Eli Lilly Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Eli Lilly Recent Developments
11.5 Merck Serono
11.5.1 Merck Serono Corporation Information
11.5.2 Merck Serono Overview
11.5.3 Merck Serono Recombinant Protein Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Merck Serono Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Merck Serono Recent Developments
11.6 Ortho Biotech
11.6.1 Ortho Biotech Corporation Information
11.6.2 Ortho Biotech Overview
11.6.3 Ortho Biotech Recombinant Protein Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Ortho Biotech Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Ortho Biotech Recent Developments
11.7 Roche
11.7.1 Roche Corporation Information
11.7.2 Roche Overview
11.7.3 Roche Recombinant Protein Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Roche Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Roche Recent Developments
11.8 Kyowa Hakko Kirin
11.8.1 Kyowa Hakko Kirin Corporation Information
11.8.2 Kyowa Hakko Kirin Overview
11.8.3 Kyowa Hakko Kirin Recombinant Protein Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Kyowa Hakko Kirin Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Kyowa Hakko Kirin Recent Developments
11.9 Pharmingen
11.9.1 Pharmingen Corporation Information
11.9.2 Pharmingen Overview
11.9.3 Pharmingen Recombinant Protein Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Pharmingen Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Pharmingen Recent Developments
11.10 Abcam
11.10.1 Abcam Corporation Information
11.10.2 Abcam Overview
11.10.3 Abcam Recombinant Protein Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Abcam Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Abcam Recent Developments
11.11 GenSci
11.11.1 GenSci Corporation Information
11.11.2 GenSci Overview
11.11.3 GenSci Recombinant Protein Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 GenSci Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 GenSci Recent Developments
11.12 SL PHARM
11.12.1 SL PHARM Corporation Information
11.12.2 SL PHARM Overview
11.12.3 SL PHARM Recombinant Protein Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 SL PHARM Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 SL PHARM Recent Developments
11.13 Dongbao Pharm
11.13.1 Dongbao Pharm Corporation Information
11.13.2 Dongbao Pharm Overview
11.13.3 Dongbao Pharm Recombinant Protein Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Dongbao Pharm Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Dongbao Pharm Recent Developments
11.14 Ankebio
11.14.1 Ankebio Corporation Information
11.14.2 Ankebio Overview
11.14.3 Ankebio Recombinant Protein Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Ankebio Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Ankebio Recent Developments
11.15 NCPC
11.15.1 NCPC Corporation Information
11.15.2 NCPC Overview
11.15.3 NCPC Recombinant Protein Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.15.4 NCPC Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 NCPC Recent Developments
11.16 Heng Rui
11.16.1 Heng Rui Corporation Information
11.16.2 Heng Rui Overview
11.16.3 Heng Rui Recombinant Protein Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.16.4 Heng Rui Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 Heng Rui Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Recombinant Protein Drugs Industry Chain Analysis
12.2 Recombinant Protein Drugs Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Recombinant Protein Drugs Production Mode & Process
12.4 Recombinant Protein Drugs Sales and Marketing
12.4.1 Recombinant Protein Drugs Sales Channels
12.4.2 Recombinant Protein Drugs Distributors
12.5 Recombinant Protein Drugs Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Recombinant Protein Drugs Industry Trends
13.2 Recombinant Protein Drugs Market Drivers
13.3 Recombinant Protein Drugs Market Challenges
13.4 Recombinant Protein Drugs Market Restraints
14 Key Findings in The Global Recombinant Protein Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
Table 1. Global Recombinant Protein Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Recombinant DNA
Table 3. Major Manufacturers of Recombinant RNA
Table 4. Global Recombinant Protein Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 5. Global Recombinant Protein Drugs Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 6. Global Recombinant Protein Drugs Sales by Region (2017-2022) & (K Doses)
Table 7. Global Recombinant Protein Drugs Sales Market Share by Region (2017-2022)
Table 8. Global Recombinant Protein Drugs Sales by Region (2023-2028) & (K Doses)
Table 9. Global Recombinant Protein Drugs Sales Market Share by Region (2023-2028)
Table 10. Global Recombinant Protein Drugs Revenue by Region (2017-2022) & (US$ Million)
Table 11. Global Recombinant Protein Drugs Revenue Market Share by Region (2017-2022)
Table 12. Global Recombinant Protein Drugs Revenue by Region (2023-2028) & (US$ Million)
Table 13. Global Recombinant Protein Drugs Revenue Market Share by Region (2023-2028)
Table 14. Global Recombinant Protein Drugs Sales by Manufacturers (2017-2022) & (K Doses)
Table 15. Global Recombinant Protein Drugs Sales Share by Manufacturers (2017-2022)
Table 16. Global Recombinant Protein Drugs Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 17. Global Recombinant Protein Drugs Revenue Share by Manufacturers (2017-2022)
Table 18. Recombinant Protein Drugs Price by Manufacturers (2017-2022) &(USD/Dose)
Table 19. Global Recombinant Protein Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 20. Global Recombinant Protein Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Protein Drugs as of 2021)
Table 21. Recombinant Protein Drugs Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Recombinant Protein Drugs Product Offered
Table 23. Date of Manufacturers Enter into Recombinant Protein Drugs Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Recombinant Protein Drugs Sales by Type (2017-2022) & (K Doses)
Table 26. Global Recombinant Protein Drugs Sales by Type (2023-2028) & (K Doses)
Table 27. Global Recombinant Protein Drugs Sales Share by Type (2017-2022)
Table 28. Global Recombinant Protein Drugs Sales Share by Type (2023-2028)
Table 29. Global Recombinant Protein Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 30. Global Recombinant Protein Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 31. Global Recombinant Protein Drugs Revenue Share by Type (2017-2022)
Table 32. Global Recombinant Protein Drugs Revenue Share by Type (2023-2028)
Table 33. Recombinant Protein Drugs Price by Type (2017-2022) & (USD/Dose)
Table 34. Global Recombinant Protein Drugs Price Forecast by Type (2023-2028) & (USD/Dose)
Table 35. Global Recombinant Protein Drugs Sales by Application (2017-2022) & (K Doses)
Table 36. Global Recombinant Protein Drugs Sales by Application (2023-2028) & (K Doses)
Table 37. Global Recombinant Protein Drugs Sales Share by Application (2017-2022)
Table 38. Global Recombinant Protein Drugs Sales Share by Application (2023-2028)
Table 39. Global Recombinant Protein Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 40. Global Recombinant Protein Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 41. Global Recombinant Protein Drugs Revenue Share by Application (2017-2022)
Table 42. Global Recombinant Protein Drugs Revenue Share by Application (2023-2028)
Table 43. Recombinant Protein Drugs Price by Application (2017-2022) & (USD/Dose)
Table 44. Global Recombinant Protein Drugs Price Forecast by Application (2023-2028) & (USD/Dose)
Table 45. North America Recombinant Protein Drugs Sales by Type (2017-2022) & (K Doses)
Table 46. North America Recombinant Protein Drugs Sales by Type (2023-2028) & (K Doses)
Table 47. North America Recombinant Protein Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 48. North America Recombinant Protein Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 49. North America Recombinant Protein Drugs Sales by Application (2017-2022) & (K Doses)
Table 50. North America Recombinant Protein Drugs Sales by Application (2023-2028) & (K Doses)
Table 51. North America Recombinant Protein Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 52. North America Recombinant Protein Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 53. North America Recombinant Protein Drugs Sales by Country (2017-2022) & (K Doses)
Table 54. North America Recombinant Protein Drugs Sales by Country (2023-2028) & (K Doses)
Table 55. North America Recombinant Protein Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 56. North America Recombinant Protein Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 57. Europe Recombinant Protein Drugs Sales by Type (2017-2022) & (K Doses)
Table 58. Europe Recombinant Protein Drugs Sales by Type (2023-2028) & (K Doses)
Table 59. Europe Recombinant Protein Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 60. Europe Recombinant Protein Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 61. Europe Recombinant Protein Drugs Sales by Application (2017-2022) & (K Doses)
Table 62. Europe Recombinant Protein Drugs Sales by Application (2023-2028) & (K Doses)
Table 63. Europe Recombinant Protein Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 64. Europe Recombinant Protein Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 65. Europe Recombinant Protein Drugs Sales by Country (2017-2022) & (K Doses)
Table 66. Europe Recombinant Protein Drugs Sales by Country (2023-2028) & (K Doses)
Table 67. Europe Recombinant Protein Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 68. Europe Recombinant Protein Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 69. Asia Pacific Recombinant Protein Drugs Sales by Type (2017-2022) & (K Doses)
Table 70. Asia Pacific Recombinant Protein Drugs Sales by Type (2023-2028) & (K Doses)
Table 71. Asia Pacific Recombinant Protein Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 72. Asia Pacific Recombinant Protein Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 73. Asia Pacific Recombinant Protein Drugs Sales by Application (2017-2022) & (K Doses)
Table 74. Asia Pacific Recombinant Protein Drugs Sales by Application (2023-2028) & (K Doses)
Table 75. Asia Pacific Recombinant Protein Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 76. Asia Pacific Recombinant Protein Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 77. Asia Pacific Recombinant Protein Drugs Sales by Region (2017-2022) & (K Doses)
Table 78. Asia Pacific Recombinant Protein Drugs Sales by Region (2023-2028) & (K Doses)
Table 79. Asia Pacific Recombinant Protein Drugs Revenue by Region (2017-2022) & (US$ Million)
Table 80. Asia Pacific Recombinant Protein Drugs Revenue by Region (2023-2028) & (US$ Million)
Table 81. Latin America Recombinant Protein Drugs Sales by Type (2017-2022) & (K Doses)
Table 82. Latin America Recombinant Protein Drugs Sales by Type (2023-2028) & (K Doses)
Table 83. Latin America Recombinant Protein Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 84. Latin America Recombinant Protein Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 85. Latin America Recombinant Protein Drugs Sales by Application (2017-2022) & (K Doses)
Table 86. Latin America Recombinant Protein Drugs Sales by Application (2023-2028) & (K Doses)
Table 87. Latin America Recombinant Protein Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 88. Latin America Recombinant Protein Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 89. Latin America Recombinant Protein Drugs Sales by Country (2017-2022) & (K Doses)
Table 90. Latin America Recombinant Protein Drugs Sales by Country (2023-2028) & (K Doses)
Table 91. Latin America Recombinant Protein Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 92. Latin America Recombinant Protein Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 93. Middle East and Africa Recombinant Protein Drugs Sales by Type (2017-2022) & (K Doses)
Table 94. Middle East and Africa Recombinant Protein Drugs Sales by Type (2023-2028) & (K Doses)
Table 95. Middle East and Africa Recombinant Protein Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 96. Middle East and Africa Recombinant Protein Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 97. Middle East and Africa Recombinant Protein Drugs Sales by Application (2017-2022) & (K Doses)
Table 98. Middle East and Africa Recombinant Protein Drugs Sales by Application (2023-2028) & (K Doses)
Table 99. Middle East and Africa Recombinant Protein Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 100. Middle East and Africa Recombinant Protein Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 101. Middle East and Africa Recombinant Protein Drugs Sales by Country (2017-2022) & (K Doses)
Table 102. Middle East and Africa Recombinant Protein Drugs Sales by Country (2023-2028) & (K Doses)
Table 103. Middle East and Africa Recombinant Protein Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 104. Middle East and Africa Recombinant Protein Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 105. Novo Nordisk Corporation Information
Table 106. Novo Nordisk Description and Major Businesses
Table 107. Novo Nordisk Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 108. Novo Nordisk Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 109. Novo Nordisk Recent Developments
Table 110. Amgen Corporation Information
Table 111. Amgen Description and Major Businesses
Table 112. Amgen Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 113. Amgen Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 114. Amgen Recent Developments
Table 115. Sanofi Corporation Information
Table 116. Sanofi Description and Major Businesses
Table 117. Sanofi Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 118. Sanofi Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 119. Sanofi Recent Developments
Table 120. Eli Lilly Corporation Information
Table 121. Eli Lilly Description and Major Businesses
Table 122. Eli Lilly Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 123. Eli Lilly Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 124. Eli Lilly Recent Developments
Table 125. Merck Serono Corporation Information
Table 126. Merck Serono Description and Major Businesses
Table 127. Merck Serono Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 128. Merck Serono Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 129. Merck Serono Recent Developments
Table 130. Ortho Biotech Corporation Information
Table 131. Ortho Biotech Description and Major Businesses
Table 132. Ortho Biotech Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 133. Ortho Biotech Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 134. Ortho Biotech Recent Developments
Table 135. Roche Corporation Information
Table 136. Roche Description and Major Businesses
Table 137. Roche Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 138. Roche Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 139. Roche Recent Developments
Table 140. Kyowa Hakko Kirin Corporation Information
Table 141. Kyowa Hakko Kirin Description and Major Businesses
Table 142. Kyowa Hakko Kirin Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 143. Kyowa Hakko Kirin Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 144. Kyowa Hakko Kirin Recent Developments
Table 145. Pharmingen Corporation Information
Table 146. Pharmingen Description and Major Businesses
Table 147. Pharmingen Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 148. Pharmingen Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 149. Pharmingen Recent Developments
Table 150. Abcam Corporation Information
Table 151. Abcam Description and Major Businesses
Table 152. Abcam Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 153. Abcam Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 154. Abcam Recent Developments
Table 155. GenSci Corporation Information
Table 156. GenSci Description and Major Businesses
Table 157. GenSci Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 158. GenSci Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 159. GenSci Recent Developments
Table 160. SL PHARM Corporation Information
Table 161. SL PHARM Description and Major Businesses
Table 162. SL PHARM Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 163. SL PHARM Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 164. SL PHARM Recent Developments
Table 165. Dongbao Pharm Corporation Information
Table 166. Dongbao Pharm Description and Major Businesses
Table 167. Dongbao Pharm Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 168. Dongbao Pharm Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 169. Dongbao Pharm Recent Developments
Table 170. Ankebio Corporation Information
Table 171. Ankebio Description and Major Businesses
Table 172. Ankebio Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 173. Ankebio Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 174. Ankebio Recent Developments
Table 175. NCPC Corporation Information
Table 176. NCPC Description and Major Businesses
Table 177. NCPC Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 178. NCPC Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 179. NCPC Recent Developments
Table 180. Heng Rui Corporation Information
Table 181. Heng Rui Description and Major Businesses
Table 182. Heng Rui Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 183. Heng Rui Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 184. Heng Rui Recent Developments
Table 185. Key Raw Materials Lists
Table 186. Raw Materials Key Suppliers Lists
Table 187. Recombinant Protein Drugs Distributors List
Table 188. Recombinant Protein Drugs Customers List
Table 189. Recombinant Protein Drugs Market Trends
Table 190. Recombinant Protein Drugs Market Drivers
Table 191. Recombinant Protein Drugs Market Challenges
Table 192. Recombinant Protein Drugs Market Restraints
Table 193. Research Programs/Design for This Report
Table 194. Key Data Information from Secondary Sources
Table 195. Key Data Information from Primary Sources
List of Figures
Figure 1. Recombinant Protein Drugs Product Picture
Figure 3. Global Recombinant Protein Drugs Market Share by Type in 2021 & 2028
Figure 3. Recombinant DNA Product Picture
Figure 4. Recombinant RNA Product Picture
Figure 5. Global Recombinant Protein Drugs Market Share by Application in 2021 & 2028
Figure 6. Pharmaceutical Industry
Figure 7. Others
Figure 8. Recombinant Protein Drugs Report Years Considered
Figure 9. Global Recombinant Protein Drugs Sales 2017-2028 (K Doses)
Figure 10. Global Recombinant Protein Drugs Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 11. Global Recombinant Protein Drugs Revenue 2017-2028 (US$ Million)
Figure 12. Global Recombinant Protein Drugs Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 13. Global Recombinant Protein Drugs Sales Market Share by Region (2017-2022)
Figure 14. Global Recombinant Protein Drugs Sales Market Share by Region (2023-2028)
Figure 15. North America Recombinant Protein Drugs Sales YoY (2017-2028) & (K Doses)
Figure 16. North America Recombinant Protein Drugs Revenue YoY (2017-2028) & (US$ Million)
Figure 17. Europe Recombinant Protein Drugs Sales YoY (2017-2028) & (K Doses)
Figure 18. Europe Recombinant Protein Drugs Revenue YoY (2017-2028) & (US$ Million)
Figure 19. Asia-Pacific Recombinant Protein Drugs Sales YoY (2017-2028) & (K Doses)
Figure 20. Asia-Pacific Recombinant Protein Drugs Revenue YoY (2017-2028) & (US$ Million)
Figure 21. Latin America Recombinant Protein Drugs Sales YoY (2017-2028) & (K Doses)
Figure 22. Latin America Recombinant Protein Drugs Revenue YoY (2017-2028) & (US$ Million)
Figure 23. Middle East & Africa Recombinant Protein Drugs Sales YoY (2017-2028) & (K Doses)
Figure 24. Middle East & Africa Recombinant Protein Drugs Revenue YoY (2017-2028) & (US$ Million)
Figure 25. The Recombinant Protein Drugs Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 26. The Top 5 and 10 Largest Manufacturers of Recombinant Protein Drugs in the World: Market Share by Recombinant Protein Drugs Revenue in 2021
Figure 27. Global Recombinant Protein Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 28. Global Recombinant Protein Drugs Sales Market Share by Type (2017-2028)
Figure 29. Global Recombinant Protein Drugs Revenue Market Share by Type (2017-2028)
Figure 30. Global Recombinant Protein Drugs Sales Market Share by Application (2017-2028)
Figure 31. Global Recombinant Protein Drugs Revenue Market Share by Application (2017-2028)
Figure 32. North America Recombinant Protein Drugs Sales Market Share by Type (2017-2028)
Figure 33. North America Recombinant Protein Drugs Revenue Market Share by Type (2017-2028)
Figure 34. North America Recombinant Protein Drugs Sales Market Share by Application (2017-2028)
Figure 35. North America Recombinant Protein Drugs Revenue Market Share by Application (2017-2028)
Figure 36. North America Recombinant Protein Drugs Sales Share by Country (2017-2028)
Figure 37. North America Recombinant Protein Drugs Revenue Share by Country (2017-2028)
Figure 38. U.S. Recombinant Protein Drugs Revenue (2017-2028) & (US$ Million)
Figure 39. Canada Recombinant Protein Drugs Revenue (2017-2028) & (US$ Million)
Figure 40. Europe Recombinant Protein Drugs Sales Market Share by Type (2017-2028)
Figure 41. Europe Recombinant Protein Drugs Revenue Market Share by Type (2017-2028)
Figure 42. Europe Recombinant Protein Drugs Sales Market Share by Application (2017-2028)
Figure 43. Europe Recombinant Protein Drugs Revenue Market Share by Application (2017-2028)
Figure 44. Europe Recombinant Protein Drugs Sales Share by Country (2017-2028)
Figure 45. Europe Recombinant Protein Drugs Revenue Share by Country (2017-2028)
Figure 46. Germany Recombinant Protein Drugs Revenue (2017-2028) & (US$ Million)
Figure 47. France Recombinant Protein Drugs Revenue (2017-2028) & (US$ Million)
Figure 48. U.K. Recombinant Protein Drugs Revenue (2017-2028) & (US$ Million)
Figure 49. Italy Recombinant Protein Drugs Revenue (2017-2028) & (US$ Million)
Figure 50. Russia Recombinant Protein Drugs Revenue (2017-2028) & (US$ Million)
Figure 51. Asia Pacific Recombinant Protein Drugs Sales Market Share by Type (2017-2028)
Figure 52. Asia Pacific Recombinant Protein Drugs Revenue Market Share by Type (2017-2028)
Figure 53. Asia Pacific Recombinant Protein Drugs Sales Market Share by Application (2017-2028)
Figure 54. Asia Pacific Recombinant Protein Drugs Revenue Market Share by Application (2017-2028)
Figure 55. Asia Pacific Recombinant Protein Drugs Sales Share by Region (2017-2028)
Figure 56. Asia Pacific Recombinant Protein Drugs Revenue Share by Region (2017-2028)
Figure 57. China Recombinant Protein Drugs Revenue (2017-2028) & (US$ Million)
Figure 58. Japan Recombinant Protein Drugs Revenue (2017-2028) & (US$ Million)
Figure 59. South Korea Recombinant Protein Drugs Revenue (2017-2028) & (US$ Million)
Figure 60. India Recombinant Protein Drugs Revenue (2017-2028) & (US$ Million)
Figure 61. Australia Recombinant Protein Drugs Revenue (2017-2028) & (US$ Million)
Figure 62. Taiwan Recombinant Protein Drugs Revenue (2017-2028) & (US$ Million)
Figure 63. Indonesia Recombinant Protein Drugs Revenue (2017-2028) & (US$ Million)
Figure 64. Thailand Recombinant Protein Drugs Revenue (2017-2028) & (US$ Million)
Figure 65. Malaysia Recombinant Protein Drugs Revenue (2017-2028) & (US$ Million)
Figure 66. Philippines Recombinant Protein Drugs Revenue (2017-2028) & (US$ Million)
Figure 67. Latin America Recombinant Protein Drugs Sales Market Share by Type (2017-2028)
Figure 68. Latin America Recombinant Protein Drugs Revenue Market Share by Type (2017-2028)
Figure 69. Latin America Recombinant Protein Drugs Sales Market Share by Application (2017-2028)
Figure 70. Latin America Recombinant Protein Drugs Revenue Market Share by Application (2017-2028)
Figure 71. Latin America Recombinant Protein Drugs Sales Share by Country (2017-2028)
Figure 72. Latin America Recombinant Protein Drugs Revenue Share by Country (2017-2028)
Figure 73. Mexico Recombinant Protein Drugs Revenue (2017-2028) & (US$ Million)
Figure 74. Brazil Recombinant Protein Drugs Revenue (2017-2028) & (US$ Million)
Figure 75. Argentina Recombinant Protein Drugs Revenue (2017-2028) & (US$ Million)
Figure 76. Middle East and Africa Recombinant Protein Drugs Sales Market Share by Type (2017-2028)
Figure 77. Middle East and Africa Recombinant Protein Drugs Revenue Market Share by Type (2017-2028)
Figure 78. Middle East and Africa Recombinant Protein Drugs Sales Market Share by Application (2017-2028)
Figure 79. Middle East and Africa Recombinant Protein Drugs Revenue Market Share by Application (2017-2028)
Figure 80. Middle East and Africa Recombinant Protein Drugs Sales Share by Country (2017-2028)
Figure 81. Middle East and Africa Recombinant Protein Drugs Revenue Share by Country (2017-2028)
Figure 82. Turkey Recombinant Protein Drugs Revenue (2017-2028) & (US$ Million)
Figure 83. Saudi Arabia Recombinant Protein Drugs Revenue (2017-2028) & (US$ Million)
Figure 84. U.A.E Recombinant Protein Drugs Revenue (2017-2028) & (US$ Million)
Figure 85. Recombinant Protein Drugs Value Chain
Figure 86. Recombinant Protein Drugs Production Process
Figure 87. Channels of Distribution
Figure 88. Distributors Profiles
Figure 89. Bottom-up and Top-down Approaches for This Report
Figure 90. Data Triangulation
Figure 91. Key Executives Interviewed
Industry Market Size
